Portola raises $60 million
This article was originally published in Scrip
Portola Pharmaceuticals, a private US biotechnology company, has raised $60 million. The proceeds will be used to advance Portola's two lead antithrombotic clinical candidates, betrixaban (formerly PRT054021) and PRT060128, and to develop the company's preclinical pipeline including a Factor Xa inhibitor antidote.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.